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Objectives: Previous studies conducted on the human CFTR gene have reported that
exon 10 and its ﬂanking introns are present in multiple copies in the human genome.
The c.1392+6insC and c.1392+12G>A variations are found in all duplicated
sequences, but are not authentic mutations in CFTR. To understand the recent
evolution of this part of the genome, the comparison of this CFTR region in humans
and in 8 different primates had been performed.
Methods: DNA extraction, sequencing and BLAST analyses were performed on
the studied species.
Results and Conclusion: A homologous sequence of the CFTR gene was
obtained in the 9 species. We observed also that the two mutations are present
in the CFTR gene except for Gorilla and Human but they only reappeared in the
duplicated human sequences, suggesting that these duplications are only in human.
To explain these observations, we suggest three hypotheses which permitted to better
understand the molecular evolution of the CFTR gene in primates: duplications and
elimination of mutations on CFTR gene, or horizontal transfer and duplications, or
founder effect. Furthermore, whatever was the origin of the duplicated sequences in
Human, their presence in all individuals could be explained by a selective advantage
not yet deﬁned. These results underline the importance of studying the duplicated
sequence of the human CFTR gene that can appear in different chromosomes or in
the gene itself as example several duplications of a part of intron 24 are detected in
this intron. This study gives novel insights in understanding CFTR gene evolution
in primates and uses, for the ﬁrst time, the CFTR gene as a signiﬁcant tool in the
evolutionary medicine.
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Objectives: Cystic Fibrosis (CF) may be revealed by nasal polyposis (NP) starting
early in life. We performed CFTR DNA and messenger RNA (mRNA) analyses in
the family of a 12 y-old boy presenting with isolated NP and a normal sweat test.
Methods: Routine DNA analysis only showed the heterozygous c.2551C>T,
p.Arg851* (R851X) mutation in the child and the father. Qualitative mRNA analysis
showed partial exon 15 skipping, associated with c.2551C>T. Quantitative mRNA
analysis exhibited a signiﬁcant increase of about 30% of total CFTR mRNA in
the patient and the mother, which was the result of the heterozygous c.-2954G>A
variant in the distant promoter region, as demonstrated by in vitro luciferase assays.
Search for a 5′ alternative abnormal transcript by 5′RACE analysis revealed the
presence of a novel transcript, in which the canonical exon 1 was replaced by an
alternative exon that we called 1a-L (1a-Long).
Conclusion: This case report could represent the ﬁrst description of a CFTR
pathology associated with an increase of CFTR mRNA amount and the presence
of a novel and probably non functional transcript.
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Objectives: We studied the intronic regions of CFTR searching for novel factors
involved in the regulation of CFTR expression. About 7% of CF patients do not
bear mutations in the coding regions of CFTR; in these patients, mutations within
regulatory sequences of gene expression may be responsible of CF. A systematic
study of CFTR introns is limited by the large number of sequences. Thus, we
focused on intronic conserved sequence tag (CST), regions with a higher degree of
homology between mouse and humans, that are the result of selective evolutionary
pressure. CSTs provide a vast library of putative novel functional sites, such as non-
previously described exon and/or elements possibly playing a role in regulating the
gene expression, which may be functionally tested as well as screened for mutation
in patients, particularly in disease where the molecular analysis of the coding regions
failed in identifying a relevant number of causative mutations. In CFTR were found
52 CSTs in non-coding regions.
Methods: All CFTR intronic CSTs were analyzed by gene scanning in 25 CF pa-
tients bearing one or both undetected mutations, 45 CF patients with a known
genotype and 38 non-CF.
Conclusion: The 57.6% of the regions did not show changes, while in 42.3% of the
regions were observed 41 variants, including 16 novel. Furthermore, we selected
2 novel allelic variants for expression studies by the genetic reporter system in
different cellular systems expressing and not expressing CFTR. In various cell lines,
the ﬁrst one showed a reduced transcriptional activity of the mutated construct in
comparison to wild type; while the other one showed a increase of activity of the
mutated form.
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CFTR is stimulated when cyclic AMP levels near the plasma membrane increase
enough for protein kinase A (PKA) to be activated, triggering phosphorylation and
channel opening. However, the family of exchange proteins directly activated by
cyclic AMP (Epacs) also responds to direct binding of cAMP. Epacs are guanine
nucleotide exchange factors for Rap GTPases, which are involved in cell-cell
adhesion, cytoskeleton rearrangement and cell polarization, processes dysregulated
in cystic ﬁbrosis. Moreover, Epacs localize to the plasma membrane by scaffolding
proteins that bind CFTR and PKA, namely ezrin-radixin-moesin (ERM) proteins.
This suggests that activation of both CFTR and Epac might be spatially and
temporally coincident. However, little is known concerning the involvement of
Epacs in CFTR biology. Our aim was thus to elucidate the impact of Epacs in
CFTR biogenesis and trafﬁcking.
Here, we show that both Epacs and their effector Rap1 are expressed in A549
cells expressing CFTR under a Tet-ON promoter, CFBE lung epithelial cell lines
and primary cultures of human bronchial epithelial cells. We also show by co-
immunoprecipitation that Epac physically interacts with CFTR in A549 cells,
supporting a functional interaction between the two proteins. Lastly, preliminary
data suggest a decrease in CFTR steady-state levels when A549 cells are treated
with a membrane-permeable Epac-selective cyclic AMP analogue that does not
activate PKA. Taken together, our data support the hypothesis that Epacs may have
a negative impact on CFTR membrane trafﬁc.
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